Cicek N, Cobandede Z, Adiguzel S, Yilmaz H, Culha M
Nanomedicine (Lond). 2025; 20(5):455-466.
PMID: 39887263
PMC: 11875468.
DOI: 10.1080/17435889.2025.2459055.
Zmuda A, Kaminska W, Bartel M, Glowacka K, Chotkowski M, Medynska K
Sci Rep. 2024; 14(1):20822.
PMID: 39242631
PMC: 11379898.
DOI: 10.1038/s41598-024-67709-z.
Bhat S, Kumar V, Dhanjal D, Gandhi Y, Mishra S, Singh S
Discov Nano. 2024; 19(1):121.
PMID: 39096427
PMC: 11297894.
DOI: 10.1186/s11671-024-04072-y.
Yoon H, Savoy E, Mesbahi N, Hendricksen A, March G, Fulton M
Bioorg Med Chem Lett. 2024; 104:129712.
PMID: 38521177
PMC: 11062396.
DOI: 10.1016/j.bmcl.2024.129712.
Degerstedt O, OCallaghan P, Lerma Clavero A, Grasjo J, Eriksson O, Sjogren E
Drug Deliv Transl Res. 2023; 14(4):970-983.
PMID: 37824040
PMC: 10927899.
DOI: 10.1007/s13346-023-01445-1.
Chitosan/Alginate Nanogels Containing Multicore Magnetic Nanoparticles for Delivery of Doxorubicin.
Veloso S, Marta E, Rodrigues P, Moura C, Amorim C, Amaral V
Pharmaceutics. 2023; 15(9).
PMID: 37765164
PMC: 10538132.
DOI: 10.3390/pharmaceutics15092194.
Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stromal Cells as an Efficient Nanocarrier to Deliver siRNA or Drug to Pancreatic Cancer Cells.
Draguet F, Dubois N, Bouland C, Pieters K, Bron D, Meuleman N
Cancers (Basel). 2023; 15(11).
PMID: 37296864
PMC: 10251888.
DOI: 10.3390/cancers15112901.
Supermolecule-Drug Conjugates Based on Acid-Degradable Polyrotaxanes for pH-Dependent Intracellular Release of Doxorubicin.
Tamura A, Osawa M, Yui N
Molecules. 2023; 28(6).
PMID: 36985487
PMC: 10056152.
DOI: 10.3390/molecules28062517.
pH-Responsive Hybrid Nanoassemblies for Cancer Treatment: Formulation Development, Optimization, and In Vitro Therapeutic Performance.
Teixeira P, Adega F, Martins-Lopes P, Machado R, Lopes C, Lucio M
Pharmaceutics. 2023; 15(2).
PMID: 36839648
PMC: 9966415.
DOI: 10.3390/pharmaceutics15020326.
Flow Cytometry Detection of Anthracycline-Treated Breast Cancer Cells: An Optimized Protocol.
Catitti G, De Fabritiis S, Brocco D, Simeone P, De Bellis D, Vespa S
Curr Issues Mol Biol. 2023; 45(1):164-174.
PMID: 36661499
PMC: 9857732.
DOI: 10.3390/cimb45010013.
Spatially selective cell treatment and collection for integrative drug testing using hydrodynamic flow focusing and shifting.
Wang X, Zheng J, Iyer M, Szmelter A, Eddington D, Lee S
PLoS One. 2023; 18(1):e0279102.
PMID: 36649249
PMC: 9844832.
DOI: 10.1371/journal.pone.0279102.
Self-Assembled Daunorubicin/Epigallocatechin Gallate Nanocomplex for Synergistic Reversal of Chemoresistance in Leukemia.
Bae K, Lai F, Oruc B, Osato M, Chen Q, Kurisawa M
Int J Mol Sci. 2023; 24(1).
PMID: 36613821
PMC: 9820275.
DOI: 10.3390/ijms24010381.
Gold Nanosystems Covered with Doxorubicin/DNA Complexes: A Therapeutic Target for Prostate and Liver Cancer.
Giraldez-Perez R, Grueso E, Montero-Hidalgo A, Luque R, Carnerero J, Kuliszewska E
Int J Mol Sci. 2022; 23(24).
PMID: 36555216
PMC: 9779246.
DOI: 10.3390/ijms232415575.
Multifunctional Oxygenated Particles for Targeted Cancer Drug Delivery and Evaluation with Darkfield Hyperspectral Imaging.
Wen Y, Liu W, David B, Ren W, Irudayaraj J
ACS Omega. 2022; 7(45):41275-41283.
PMID: 36406533
PMC: 9670270.
DOI: 10.1021/acsomega.2c04953.
A Lateral Flow Device for Point-of-Care Detection of Doxorubicin.
Pomili T, Gatto F, Pompa P
Biosensors (Basel). 2022; 12(10).
PMID: 36291033
PMC: 9599782.
DOI: 10.3390/bios12100896.
Apurinic/apyrimidinic endonuclease triggered doxorubicin-releasing DNA nanoprism for target therapy.
Liang M, Li N, Liu F, Zeng N, Yu C, Li S
Cell Cycle. 2022; 21(24):2627-2634.
PMID: 35943146
PMC: 9704400.
DOI: 10.1080/15384101.2022.2108567.
Monitoring Mitochondrial Morphology and Respiration in Doxorubicin-Induced Cardiomyopathy.
Abdullah C, Aishwarya R, Morshed M, Remex N, Miriyala S, Panchatcharam M
Methods Mol Biol. 2022; 2497:207-220.
PMID: 35771444
PMC: 11118012.
DOI: 10.1007/978-1-0716-2309-1_13.
Impact of Doxorubicin on Cell-Substrate Topology.
Krecsir A, Richter V, Wagner M, Schneckenburger H
Int J Mol Sci. 2022; 23(11).
PMID: 35682954
PMC: 9181088.
DOI: 10.3390/ijms23116277.
Solid Magnetoliposomes as Multi-Stimuli-Responsive Systems for Controlled Release of Doxorubicin: Assessment of Lipid Formulations.
Cardoso B, Cardoso V, Lanceros-Mendez S, Castanheira E
Biomedicines. 2022; 10(5).
PMID: 35625942
PMC: 9138220.
DOI: 10.3390/biomedicines10051207.
Magnetic lipid nanovehicles synergize the controlled thermal release of chemotherapeutics with magnetic ablation while enabling non-invasive monitoring by MRI for melanoma theranostics.
Garcia-Hevia L, Casafont I, Oliveira J, Teran N, Fanarraga M, Gallo J
Bioact Mater. 2021; 8:153-164.
PMID: 34541393
PMC: 8424388.
DOI: 10.1016/j.bioactmat.2021.06.009.